Compare CNDT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | NYXH |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | Belgium |
| Employees | 51000 | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.6M | 161.9M |
| IPO Year | 2016 | 2021 |
| Metric | CNDT | NYXH |
|---|---|---|
| Price | $1.46 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 1.2M | 509.3K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,042,000,000.00 | N/A |
| Revenue This Year | $2.01 | $213.98 |
| Revenue Next Year | $4.06 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $1.26 |
| 52 Week High | $2.98 | $8.59 |
| Indicator | CNDT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 36.57 |
| Support Level | $1.32 | $1.26 |
| Resistance Level | $1.60 | $1.70 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 71.23 | 92.22 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.